157 related articles for article (PubMed ID: 33970392)
21. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
22. Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients.
Hayashi N; Tsunoda H; Namura M; Ochi T; Suzuki K; Yamauchi H; Nakamura S
Clin Breast Cancer; 2019 Feb; 19(1):71-77. PubMed ID: 30206035
[TBL] [Abstract][Full Text] [Related]
23. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
[TBL] [Abstract][Full Text] [Related]
24. Does Tumor Size Predict Response to Neoadjuvant Chemotherapy in the Modern Era of Biologically Driven Treatment? A Nationwide Study of US Breast Cancer Patients.
Livingston-Rosanoff D; Schumacher J; Vande Walle K; Stankowski-Drengler T; Greenberg CC; Neuman H; Wilke LG
Clin Breast Cancer; 2019 Dec; 19(6):e741-e747. PubMed ID: 31300338
[TBL] [Abstract][Full Text] [Related]
25. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
[TBL] [Abstract][Full Text] [Related]
27. Multiparametric monitoring of chemotherapy treatment response in locally advanced breast cancer using quantitative ultrasound and diffuse optical spectroscopy.
Tran WT; Childs C; Chin L; Slodkowska E; Sannachi L; Tadayyon H; Watkins E; Wong SL; Curpen B; El Kaffas A; Al-Mahrouki A; Sadeghi-Naini A; Czarnota GJ
Oncotarget; 2016 Apr; 7(15):19762-80. PubMed ID: 26942698
[TBL] [Abstract][Full Text] [Related]
28. A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
Risi E; Grilli A; Migliaccio I; Biagioni C; McCartney A; Guarducci C; Bonechi M; Benelli M; Vitale S; Biganzoli L; Bicciato S; Di Leo A; Malorni L
Breast Cancer Res Treat; 2018 Jul; 170(2):329-341. PubMed ID: 29564743
[TBL] [Abstract][Full Text] [Related]
29. Laboratory indicators predict axillary nodal pathologic complete response after neoadjuvant therapy in breast cancer.
Chen P; Zhao T; Bi Z; Zhang ZP; Xie L; Liu YB; Song XG; Song XR; Wang CJ; Wang YS
Future Oncol; 2021 Jul; 17(19):2449-2460. PubMed ID: 33878939
[TBL] [Abstract][Full Text] [Related]
30. Noninvasive monitoring of breast cancer during neoadjuvant chemotherapy using optical tomography with ultrasound localization.
Zhu Q; Tannenbaum S; Hegde P; Kane M; Xu C; Kurtzman SH
Neoplasia; 2008 Oct; 10(10):1028-40. PubMed ID: 18813360
[TBL] [Abstract][Full Text] [Related]
31. Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT.
Ueda S; Yoshizawa N; Shigekawa T; Takeuchi H; Ogura H; Osaki A; Saeki T; Ueda Y; Yamane T; Kuji I; Sakahara H
J Nucl Med; 2016 Aug; 57(8):1189-95. PubMed ID: 26940765
[TBL] [Abstract][Full Text] [Related]
32. HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment.
Groheux D; Giacchetti S; Hatt M; Marty M; Vercellino L; de Roquancourt A; Cuvier C; Coussy F; Espié M; Hindié E
Br J Cancer; 2013 Sep; 109(5):1157-64. PubMed ID: 23942075
[TBL] [Abstract][Full Text] [Related]
33. TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.
Connolly RM; Leal JP; Solnes L; Huang CY; Carpenter A; Gaffney K; Abramson V; Carey LA; Liu MC; Rimawi M; Specht J; Storniolo AM; Valero V; Vaklavas C; Krop IE; Winer EP; Camp M; Miller RS; Wolff AC; Cimino-Mathews A; Park BH; Wahl RL; Stearns V
J Clin Oncol; 2019 Mar; 37(9):714-722. PubMed ID: 30721110
[TBL] [Abstract][Full Text] [Related]
34. The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials.
Graeser M; Harbeck N; Gluz O; Würstlein R; Zu Eulenburg C; Schumacher C; Grischke EM; Forstbauer H; Dimpfl M; Braun M; Christgen M; Kreipe HH; Potenberg J; von Schumann R; Aktas B; Kolberg-Liedtke C; Kümmel S; Nitz U
Breast; 2021 Oct; 59():58-66. PubMed ID: 34166854
[TBL] [Abstract][Full Text] [Related]
35. Utility of
Lee IH; Lee SJ; Lee J; Jung JH; Park HY; Jeong SY; Lee SW; Chae YS
BMC Cancer; 2020 Nov; 20(1):1106. PubMed ID: 33198673
[TBL] [Abstract][Full Text] [Related]
36. Ultrasound and clinicopathological characteristics-based model for prediction of pathologic response to neoadjuvant chemotherapy in HER2-positive breast cancer: a case-control study.
Sui L; Yan Y; Jiang T; Ou D; Chen C; Lai M; Ni C; Zhu X; Wang L; Yang C; Li W; Yao J; Xu D
Breast Cancer Res Treat; 2023 Nov; 202(1):45-55. PubMed ID: 37639063
[TBL] [Abstract][Full Text] [Related]
37. Ultrasound-Guided Diffuse Optical Tomography for Predicting and Monitoring Neoadjuvant Chemotherapy of Breast Cancers: Recent Progress.
Xu C; Vavadi H; Merkulov A; Li H; Erfanzadeh M; Mostafa A; Gong Y; Salehi H; Tannenbaum S; Zhu Q
Ultrason Imaging; 2016 Jan; 38(1):5-18. PubMed ID: 25887527
[TBL] [Abstract][Full Text] [Related]
38. Utility of MRI and PET/CT after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity.
Kim T; Kang DK; An YS; Yim H; Jung YS; Kim KS; Kang SY; Kim TH
Acta Radiol; 2014 May; 55(4):399-408. PubMed ID: 23963151
[TBL] [Abstract][Full Text] [Related]
39. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
[TBL] [Abstract][Full Text] [Related]
40. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]